J&J/USAID – Access Program

Program Objectives

This program aims at ensuring responsible access and appropriate use of anti-MDR-TB treatment. J&J commitment builds upon and strengthens the Company’s agreement with the Stop TB Partnership’s Global Drug Facility to facilitate access to quality-assured medicines in more than 100 countries worldwide.

J&J, USAID, and its partners are engaging with National TB programs to build systems, infrastructure and competencies. J&J, USAID, and its partners are engaging with National TB programs to build systems, infrastructure and competencies. Copyright J&J

What are the health needs and challenges?

Antimicrobial resistance – and specifically that seen in multidrug-resistant tuberculosis (MDR-TB) – is one of the world’s most serious public health threats. MDR-TB is resistant to at least two of the four most commonly used medicines in today’s standard treatment regimen. Despite the development of new MDR-TB treatment options, the ability to scale up the appropriate use of treatment regimens remains very challenging given weak health care infrastructures, which typically exist in vulnerable countries. However, in order to prevent further resistance, it is essential to ensure responsible access to new treatment options in these countries, including accurate diagnosis and documentation of use and impact.

Description of partnership activities and how they address needs and challenges

In March 2015, J&J and USAID formalized a collaboration that leverages the expertise and capabilities of two of the largest private and public organizations engaged in the global TB effort to implement a responsible introduction of J&J anti-MDR TB treatment in more than 100 countries. J&J will contribute up to 30,000 treatments of its anti-TB treatment valued at $30 million USD, to USAID’s global system-strengthening, data collection, and medical educational efforts. In January 2016, Johnson & Johnson announced a $15-20 million pledge as part of a new partnership with USAID to combat Multidrug-Resistant Tuberculosis (MDR-TB). Since the launch of the J&J/USAID donation program in April of 2015, 38 countries have reached out to the Global Drug Facility to access anti-MDR-TB treatment through the donation program. J&J, USAID, and its partners are engaging with National TB programs to build systems, infrastructure and competencies to ensure appropriate patient identification, optimize treatment regimens, and bolster patient monitoring and pharmacovigilance.

Corresponding principle in the declaration

“As part of the WHO Global Action Plan’s proposal for a comprehensive program of sanitation, hygiene, vaccination, infection control, education, and stewardship, we support mechanisms to ensure affordable access to new and existing antibiotics to the patients who need them, in all parts of the world and at all levels of income."

Read full Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance (AMR)



Partnership information

Company(ies) Johnson & Johnson

Partner(s) US Agency for International Development (USAID)

Type of Partner(s) Government

Therapeutic Focus Infectious Diseases

Disease(s) Drug-Resistant Infections (AMR)

Program Type(s) Health System Infrastructure - Development of Physical Infrastructure, Health System Infrastructure - Outreach & Medical Services, Research & Development - Innovative Funding Mechanisms

Region(s)

Start Date 2015

More information Press Release Fighting Multi-Drug Resistant Tuberculosis (MDR-TB)

Anticipated completion date Ongoing